Effects of aprotinin on gene expression and protein synthesis after ischemia and reperfusion in rats

Circulation

Volumn 116, Issue 11 SUPPL. 1, 2007, Pages

  Buerke, Michael ^a   Pruefer, Diethard ^b   Sankat, Dennis ^a   Carter, Justin M ^a   Buerke, Ute ^a   Russ, Martin ^a   Schlitt, Axel ^a   Friedrich, Ivar ^a   Börgermann, Jochen ^a   Vahl, Christian F ^b   Werdan, Karl ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Gene expression profiling; Ischemia reperfusion injury; Leukocytes; Protein synthesis

Indexed keywords

APROTININ; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REPERFUSION INJURY;

ANIMALS; APROTININ; GENE EXPRESSION REGULATION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; PROTEIN BIOSYNTHESIS; RATS;

EID: 34748914326     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.680249     Document Type: Article

References (25)

1. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999;43:860-878.
2. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
3. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006;46:327-338.
4. Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg. 2006;103:1074-1081.
5. Lazar HL, Bao Y, Tanzillo L, O'Gara P, Reardon D, Price D, Crowley R, Cabral HJ. Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg. 2005;20:519-523.
6. Royston D, Levy JH, Fitch J, Dietrich W, Body SC, Murkin JM, Spiess BD, Nadel A. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg. 2006;103:1082-1088.
7. Khan TA, Bianchi C, Voisine P, Feng J, Baker J, Hart M, Takahashi M, Stahl G, Sellke FW. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg. 2004;128:602-608.
8. Bull DA, Maurer J. Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg. 2003;75:S735-739.
9. Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med. 2005;15:302-308.
10. Rossi A, Elia G, Santoro MG. Activation of the heat shock factor 1 by serine protease inhibitors: an effect associated with nuclear factor-kappa B inhibition. J Biol Chem. 1998;273:16446-16452.
11. Pruefer D, Makowski J, Dahm M, Guth S, Oelert H, Darius H, Buerke M. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg. 2003; 75:210-215; discussion 215-216.
12. Buerke M, Prufer D, Dahm M, Oelert H, Meyer J, Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther. 1998;286:429-438.
13. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A. 1995;92:8031-8035.
14. Taira Y, Kanaide H, Nakamura M. The distribution of ischaemia in perfused Wistar rat hearts following coronary artery occlusion. Br J Exp Pathol. 1985;66:613-621.
15. Kjekshus JK, Sobel BE. Depressed myocardial creatine phosphokinase activity following experimental myocardial infarction in rabbit. Circ Res. 1970;27:403-414.
16. Hilker M, Langin T, Hake U, Schmid FX, Kuroczynski W, Lehr HA, Oelert H, Buerke M. Gene expression profiling of human stenotic aortocoronary bypass grafts by cDNA array analysis. Eur J Cardiothorac Surg. 2003;23:620-625.
17. Burysek L, Syrovets T, Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem. 2002;277:33509-33517.
18. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason JC, Ratnatunga CP, Haskard DO, Taylor KM, Landis RC. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000;120:361-369.
19. Harmon D, Ghori K, Lan W, Shorten G. Effect of aprotinin on in vitro cerebral endothelial ICAM-1 expression induced by astrocyte-conditioned medium. Eur J Anaesthesiol. 2005;22:277-282.
20. Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg. 2001;122:123-128.
21. Lorant DE, Topham MK, Whatley RE, McEver RP, McIntyre TM, Prescott SM, Zimmerman GA. Inflammatory roles of P-selectin. J Clin Invest. 1993;92:559-570.
22. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
23. Weyrich AS, Buerke M, Albertine KH, Lefer AM. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J Leukoc Biol. 1995;57:45-55.
24. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 2000;69:1084-1091.
25. Kawauchi J, Zhang C, Nobori K, Hashimoto Y, Adachi MT, Noda A, Sunamori M, Kitajima S. Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription. J Biol Chem. 2002;277:39025-39034.